Mineralys (NASDAQ: MLYS) CCO sells shares after option exercise

Rhea-AI Filing Summary

Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised stock options and sold shares in a planned transaction. He exercised options for 104,124 shares of common stock at $13.24 per share and sold 104,124 shares at a weighted-average price of $25.8953 per share.

These trades were carried out under a Rule 10b5-1 stock selling plan adopted on March 27, 2026, indicating they were pre-scheduled. Following the transactions, Warren directly owns 38,400 shares of Mineralys common stock.

Insider Trade Summary 10b5-1

Net Seller: 104,124 shares ($2,696,322)

Net Sell 3 txns

Insider Warren Eric

Role Chief Commercial Officer

Sold 104,124 shs ($2.70M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	104,124	$0.00	--
Exercise	Common Stock	104,124	$13.24	$1.38M
Sale	Common Stock	104,124	$25.8953	$2.70M

Holdings After Transaction: Stock Option — 252,876 shares (Direct, null); Common Stock — 142,524 shares (Direct, null)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Shares sold: 104,124 shares Sale price: $25.8953 per share Option exercise price: $13.24 per share +3 more

6 metrics

Shares sold 104,124 shares Common stock sold on June 26, 2026

Sale price $25.8953 per share Weighted-average sale price for 104,124 shares

Option exercise price $13.24 per share Conversion price for 104,124 underlying shares

Shares after transactions 38,400 shares Common stock directly owned after June 26, 2026

Option expiration April 21, 2035 Expiration date of exercised stock option

Rule 10b5-1 plan date March 27, 2026 Adoption date of stock selling plan

Key Terms

Rule 10b5-1 stock selling plan, weighted-average price, stock option, derivative security

4 terms

Rule 10b5-1 stock selling plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026."

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

stock option financial

"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 06:41 PM Accepted by SEC EDGAR 06/30/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warren Eric

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		M(1)		104,124	A	$13.24	142,524	D
Common Stock	06/26/2026		S(1)		104,124	D	$25.8953(2)	38,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$13.24	06/26/2026		M(1)			104,124	(3)	04/21/2035	Common Stock	104,124	$0	252,876	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.8941 to $25.9100. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Mineralys Therapeutics (MLYS) report for Eric Warren?

Mineralys Therapeutics reported that Chief Commercial Officer Eric Warren exercised stock options for 104,124 shares and sold 104,124 common shares. The transactions occurred on June 26, 2026, and were executed as part of a pre-arranged Rule 10b5-1 stock selling plan.

At what prices did Eric Warren trade Mineralys Therapeutics (MLYS) shares?

Eric Warren exercised options at $13.24 per share and sold 104,124 Mineralys common shares at a weighted-average price of $25.8953. The sales occurred through multiple trades with individual prices ranging from $25.8941 to $25.9100, according to the reported Form 4 disclosure.

How many Mineralys Therapeutics (MLYS) shares does Eric Warren hold after the Form 4 transactions?

After the reported transactions, Eric Warren directly owns 38,400 shares of Mineralys Therapeutics common stock. This figure reflects his position following the exercise of 104,124 stock options and the same-day sale of 104,124 common shares disclosed in the filing.

Were Eric Warren’s Mineralys Therapeutics (MLYS) stock sales under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that Eric Warren’s transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Such plans allow insiders to schedule trades in advance, helping separate trading decisions from day-to-day market developments.

What are the details of Eric Warren’s exercised stock options in Mineralys Therapeutics (MLYS)?

Eric Warren exercised stock options covering 104,124 underlying shares of Mineralys common stock at a conversion price of $13.24 per share. The option expires on April 21, 2035, and vested 25% after one year, with the remainder vesting in 36 substantially equal monthly installments.